Sugi Predict

Sugi Predict / Targets / HEXB

HEXB

Beta-hexosaminidase subunit beta · P07686 · HEXB on Sugi Atlas →

7,890 patent compounds predicted against HEXB, 5,187 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3290712 SCHEMBL3290712 0.78 15/20
SCHEMBL3292141 SCHEMBL3292141 0.78 15/20
SCHEMBL4408773 SCHEMBL4408773 1.00 14/20
Elinafide Elinafide (SCHEMBL19067) 0.90 14/20
Elinafide Elinafide (SCHEMBL1890262) 0.76 13/20
SCHEMBL3498787 SCHEMBL3498787 1.00 8/20
SCHEMBL4415942 SCHEMBL4415942 0.70 8/20
SCHEMBL3628166 SCHEMBL3628166 0.50 8/20
SCHEMBL4147996 SCHEMBL4147996 0.48 8/20
SCHEMBL1359352 SCHEMBL1359352 0.62 7/20
SCHEMBL1885367 SCHEMBL1885367 0.50 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1889973) 0.49 7/20
Pyrimethamine Pyrimethamine (SCHEMBL25129) 1.00 6/20
SCHEMBL626424 SCHEMBL626424 1.00 6/20
SCHEMBL1357011 SCHEMBL1357011 1.00 6/20
SCHEMBL4187947 SCHEMBL4187947 0.81 6/20
SCHEMBL1899664 SCHEMBL1899664 0.77 6/20
SCHEMBL1903231 SCHEMBL1903231 0.77 6/20
SCHEMBL2365312 SCHEMBL2365312 0.74 6/20
Pyrimethamine Pyrimethamine (SCHEMBL3671657) 0.73 6/20

Clinical trials — most relevant to HEXB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI PHASE3COMPLETED
N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease) PHASE2COMPLETED
First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease) PHASE1/PHASE2COMPLETED
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI PHASE2COMPLETED
Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease PHASE2COMPLETED
A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA PHASE1/PHASE2COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease PHASE1/PHASE2SUSPENDED
Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis PHASE1WITHDRAWN
Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI PHASE1COMPLETED
Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis Clinical Trial PHASE1NOT_YET_RECRUITING
Translational Potential of ex Vivo Gene Therapy in GM2 Gangliosidosis nanNOT_YET_RECRUITING
A Natural History of Late Onset Tay-Sachs Disease nanCOMPLETED
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN
Registry Gangliosidoses nanUNKNOWN
BMN 110 US Expanded Access Program nanAPPROVED_FOR_MARKETING
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Biomarker for Hurler Disease (BioHurler) nanWITHDRAWN
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis nanCOMPLETED
Natural History of Atypical Morquio A Disease nanCOMPLETED
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption nanUNKNOWN
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease nanRECRUITING
Screening of Fabry Disease in Portuguese Patients With Idiopathic Cardiomyopathies nanCOMPLETED
Natural History of Morquio B and Late-Onset of GM1 Gangliosidosis nanUNKNOWN
Gene Therapy for Tay-Sachs Disease nanCOMPLETED
Genetic Investigations in Children With Developmental and Epileptic Encephalopathies in Ho Chi Minh City, Vietnam nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a HEXB binder may also engage these)

ProteinNameSimilarity
Q6AXR4 — 0.997 Q6AXR4 →
P20060 — 0.996 P20060 →
P49614 — 0.995 P49614 →
HEXA Beta-hexosaminidase subunit alpha 0.993 landscape →
Q641X3 — 0.992 Q641X3 →
Q29548 — 0.992 Q29548 →
P29416 — 0.991 P29416 →
Q0V8R6 — 0.990 Q0V8R6 →
Q5RC84 — 0.987 Q5RC84 →
FUCA2 Plasma alpha-L-fucosidase 0.974 landscape →
Q8K2I4 — 0.974 Q8K2I4 →
Q29444 — 0.972 Q29444 →
Q5RFI5 — 0.971 Q5RFI5 →
Q95327 — 0.970 Q95327 →
Q2M3T9 — 0.968 Q2M3T9 →
Q99KR8 — 0.967 Q99KR8 →
Q5R5N6 — 0.966 Q5R5N6 →
Q8BHN3 — 0.966 Q8BHN3 →
Q6DYE8 — 0.966 Q6DYE8 →
Q05A56 — 0.966 Q05A56 →
Q9FNA3 — 0.966 Q9FNA3 →
O97524 — 0.965 O97524 →
W8E7D1 — 0.965 W8E7D1 →
Q6AYS4 — 0.965 Q6AYS4 →
O77695 — 0.965 O77695 →
Q4FZV0 — 0.965 Q4FZV0 →
Q8L7S6 — 0.964 Q8L7S6 →
A7WM73 — 0.964 A7WM73 →
P79403 — 0.964 P79403 →
MANBA Beta-mannosidase 0.964 landscape →